Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Classical reporting system

Contexte Official surveillance system relies on official laws. The Lebanese Law related to communicable diseases issued on the 31st December 1957 requests from physicians and healthcare facilities to report to the MOPH selected communicable diseases.
On the other hand, the MOPH issues continuously decisions, circulars, and memos that specifies technical aspects of the national surveillance system (case definitions, forms…).
Objectives - Measure disease burden and describe the characteristics. This includes: a) Measure incidence, prevalence, and mortality rates; b) Describe event/disease by time, place and person; c) Monitor trends; d) Identify high risk populations or areas; e) Identify risk factors; f) Evaluate specific diseases control programs.
- Detect alerts and outbreaks. The detection of an outbreak gives an opportunity to investigate, find etiologies and implement corrective measures, thus aiming to reduce cases and prevent later outbreaks. Early warning and response system refers to the outbreak detection at early stages; when timely corrective measures can prevent additional new cases and stop the natural evolution of the outbreak.
Target diseases and syndromes 40 diseases and syndromes are targetted by the classical surveillance system. The diseases are displayed in 2 groups: immediate notification and weekly notification:
- The immediate notifiable diseases and syndromes are: Acute Flaccid Paralysis, Anthrax, Cholera, Diphtheria, Food Poisoning, Hemorrhagic Fever, Influenza novel viruses, Invasive Coranaviruses, Measles, Meningitis, Meningococcal infection, Mumps, Pertussis, Plague, Rabies, Rubella and Congenital Rubella Syndrome, Smallpox, Tetanus including Tetanus Neonatorum, and Unusual Event
- The weekly notifiable diseases and syndromes are: Bilharziasis, Brucellosis, Creutzfeldt-Jakob Disease (Transmissible Spongiform Encephalopathy), Gonococcal Infection,Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, Hepatitis E, Human Immunodeficiency Virus, Human T-cell Lymphotropic Virus 1, Hydatid Disease, Intestinal Infections, Legionellosis, Leishmaniasis, Leprosy, Malaria, Syphilis, Tuberculosis, Typhoid Fever and Typhus.  
Data Sources All Physicians and Healthcare facilities
Guidelines - Communicable diseases surveillance guideline: Ar, En
- Communicable diseases surveillance standard operating procedures - part 1 (immediately notifiable diseases): En
- Communicable diseases surveillance standard operating procedures - part 2 (weekly notifiable diseases): En
Case definitions Refer to webpages "Notifiable Diseases"
Form Reporting form
Results Refer to webpage "Surveillance data"
    3
    ...
ATC Name B/G Ingredients Dosage Form Price
C09AA05 TRILTEC G Ramipril - 1.25mg 1.25mg Capsule 524,739 L.L
L04AD02 PROGRAF 1MG B Tacrolimus - 1mg 1mg Capsule L.L
L04AX02 THALIDOMIDE BMS B Thalidomide - 50mg 50mg Capsule 27,387,764 L.L
L04AD02 PROGRAF 5MG B Tacrolimus - 5mg 5mg Capsule L.L
L04AX02 THALIDOMIDE CELGENE B Thalidomide - 50mg 50mg Capsule 27,387,764 L.L
C09AA05 APO-RAMIPRIL G Ramipril - 2.5mg 2.5mg Capsule 463,626 L.L
M03BB53 PARAXONE-JPI G Paracetamol - 300mg, Chlorzoxazone - 250mg Capsule 334,617 L.L
A02BC01 AXIPRON G Omeprazole - 20mg 20mg Capsule 373,358 L.L
J01CA01 ANTALPEN G Ampicillin (trihydrate) - 250mg 250mg Capsule 218,854 L.L
M03BB53 RELAXON G Paracetamol - 300mg, Chlorzoxazone - 250mg Capsule 296,989 L.L
A02BC01 DIGCAP G Omeprazole - 20mg 20mg Capsule 593,850 L.L
C09AA05 TRILTEC G Ramipril - 2.5mg 2.5mg Capsule 255,970 L.L
J01CA01 ANTALPEN G Ampicillin (trihydrate) - 500mg 500mg Capsule 285,407 L.L
L04AX04 REVLIMID B Lenalidomide - 10mg 10mg Capsule L.L
A02BC01 EPIRAZOLE G Omeprazole - 20mg 20mg Capsule 208,296 L.L
A02BC01 GASTRAZOLE G Omeprazole - 20mg 20mg Capsule 185,450 L.L
A02BC01 GASTRAZOLE G Omeprazole - 20mg 20mg Capsule 377,620 L.L
C09AA05 APO-RAMIPRIL G Ramipril - 5mg 5mg Capsule 794,211 L.L
J01CA04 AMOXICILLIN G Amoxicillin (trihydrate) - 500mg 500mg Capsule 6,199,145 L.L
J01CA04 AMOXICILLINE ARROW LAB G Amoxicillin (trihydrate) - 500mg 500mg Capsule 564,414 L.L
L04AX04 REVLIMID B Lenalidomide - 5mg 5mg Capsule 105,106,076 L.L
J01CA04 AMOXIDREX G Amoxicillin (trihydrate) - 500mg 500mg Capsule 254,690 L.L
L04AX04 APO-LENALIDOMIDE G Lenalidomide - 5mg 5mg Capsule 49,795,454 L.L
A02BC01 GASTRISEC G Omeprazole - 20mg 20mg Capsule 413,903 L.L
C09AA05 TRILTEC G Ramipril - 5mg 5mg Capsule 447,948 L.L
J01CA04 AMOXIDREX G Amoxicillin (trihydrate) - 500mg 500mg Capsule 7,332,097 L.L
N02BE51 PARACETAMOL/CAFEINE/CODEINE BIOGARAN G Paracetamol - 400mg, Caffeine - 50mg, Codeine - 20mg Capsule 548,288 L.L
A02BC01 HYPOSEC G Omeprazole - 20mg 20mg Capsule 659,827 L.L
A07AA02 MEDISTAN G Nystatin - 500,000IU 500,000IU Capsule 417,231 L.L
J01CA04 AMOXYCILLIN G Amoxicillin (trihydrate) - 500mg 500mg Capsule 4,073,187 L.L
    3
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2026